Toronto Dominion Bank Acquires 9,076 Shares of Hologic, Inc. (NASDAQ:HOLX)

Toronto Dominion Bank boosted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,308 shares of the medical equipment provider's stock after purchasing an additional 9,076 shares during the quarter. Toronto Dominion Bank owned approximately 0.06% of Hologic worth $8,961,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Barclays PLC boosted its stake in Hologic by 47.6% in the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after purchasing an additional 231,578 shares during the period. LaFleur & Godfrey LLC boosted its stake in Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock worth $9,399,000 after purchasing an additional 3,655 shares during the period. Blue Trust Inc. boosted its stake in Hologic by 18.4% in the 4th quarter. Blue Trust Inc. now owns 8,428 shares of the medical equipment provider's stock worth $608,000 after purchasing an additional 1,310 shares during the period. KBC Group NV boosted its stake in Hologic by 6.6% in the 4th quarter. KBC Group NV now owns 93,376 shares of the medical equipment provider's stock worth $6,731,000 after purchasing an additional 5,747 shares during the period. Finally, Custom Index Systems LLC boosted its stake in Hologic by 7.1% in the 4th quarter. Custom Index Systems LLC now owns 9,379 shares of the medical equipment provider's stock worth $676,000 after purchasing an additional 618 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent analyst reports. Raymond James restated an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada decreased their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Finally, Citigroup decreased their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $77.42.

Hologic Trading Down 0.3%

NASDAQ:HOLX traded down $0.16 during midday trading on Monday, hitting $62.01. 2,584,438 shares of the company traded hands, compared to its average volume of 2,269,873. The firm's fifty day moving average is $58.15 and its 200-day moving average is $65.69. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The firm has a market capitalization of $13.82 billion, a P/E ratio of 19.56, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the firm posted $1.03 earnings per share. The business's revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.